Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6643524 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL23698756 | 1.00 | — | — | |
| SCHEMBL3464926 | 0.98 | — | — | |
| SCHEMBL481870 | 0.98 | — | — | |
| SCHEMBL1321291 | 0.98 | — | — | |
| SCHEMBL22335396 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL481715 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL21408413 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL17203364 | 0.85 | — | — | |
| SCHEMBL3464740 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332138-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER | VIVOZON, INC. (KR) | 2025-10-30 | — | — | US | disclosed |
| US-12435051-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | VIVOZON, INC. (KR) | 2025-10-07 | — | — | US | disclosed |
| US-12371431-B2 | Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| US-12319689-B2 | Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-06-03 | — | — | US | disclosed |
| CN-116234552-B | Dual modulators of mGluR5 and 5-HT2A receptors and uses thereof | (株)倍宝尊 | 2025-02-25 | — | — | CN | disclosed |
| EP-4470534-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER | Vivozon, Inc. (KR) | 2024-12-04 | — | — | EP | disclosed |
| US-20240360092-A1 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | VIVOZON INC. (KR) | 2024-10-31 | — | — | US | disclosed |
| CN-118695858-A | Pharmaceutical composition for preventing or treating mental disorder | (株)倍宝尊 | 2024-09-24 | — | — | CN | disclosed |
| US-12060339-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | VIVOZON INC. (KR) | 2024-08-13 | — | — | US | disclosed |
| CN-113825754-B | Disubstituted sulfonamide selective BCL-2 inhibitors including methyl and trifluoromethyl | 正大天晴药业集团股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116234552-A | Dual modulators of mGluR5 and 5-HT2A receptors and uses thereof | (株)倍宝尊 | 2023-06-06 | — | — | CN | disclosed |
| CN-116199686-A | Trifluoromethyl substituted sulfonamide compounds | 正大天晴药业集团股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-112888687-B | Trifluoromethyl substituted sulfonamides selective BCL-2 inhibitors | 正大天晴药业集团股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-20220274939-A1 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | VIVOZON INC. (KR) | 2022-09-01 | — | — | US | disclosed |
| US-20220220110-A1 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| EP-3978494-A1 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-04-06 | — | — | EP | disclosed |
| US-20220002290-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| CN-113825754-A | Selective BCL-2 inhibitors of disubstituted sulfonamides including methyl and trifluoromethyl | 正大天晴药业集团股份有限公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3858832-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| CN-112888687-A | Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors | 正大天晴药业集团股份有限公司 | 2021-06-01 | — | — | CN | disclosed |